Innoviva (INVA) Intangibles (2013 - 2026)
Innoviva posted quarterly Intangibles of $175.6 million for Q1 2026, down 32.9% year-on-year from $261.7 million in Q1 2025, and down 3.6% on a QoQ basis from $182.2 million in Q4 2025.
Innoviva (INVA) has 7 years of Intangibles data on file, last reported at $175.6 million in Q1 2026.
- For the quarter ending Q1 2026, Intangibles fell 32.9% year-over-year to $175.6 million; the trailing twelve-month figure through Mar 2026 stood at $175.6 million (down 32.9% YoY), and the FY2025 full-year result was $182.2 million, down 12.61% from the prior year.
- Intangibles for Q1 2026 stood at $175.6 million, down from $182.2 million in the prior quarter.
- Across five years, Intangibles topped out at $261.7 million in Q1 2025 and bottomed at $35.5 million in Q2 2022.
- The 5-year median for Intangibles is $223.9 million (2024), against an average of $211.5 million.
- The widest annual swing landed in 2023, when Intangibles surged 625.92%; it then plunged 32.9% in 2026.
- A 5-year view of Intangibles shows it stood at $258.5 million in 2022, then declined by 0.31% to $257.7 million in 2023, then fell by 19.12% to $208.4 million in 2024, then dropped by 12.61% to $182.2 million in 2025, then dropped by 3.6% to $175.6 million in 2026.
- The last three Intangibles figures came in at $175.6 million (Q1 2026), $182.2 million (Q4 2025), and $261.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 175.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 175.60 Mn |
| Dec 31, 2025 | 182.16 Mn |
| Sep 30, 2025 | 261.70 Mn |
| Jun 30, 2025 | 195.41 Mn |
| Mar 31, 2025 | 261.70 Mn |
| Dec 31, 2024 | 208.43 Mn |
| Sep 30, 2024 | 210.94 Mn |
| Jun 30, 2024 | 217.46 Mn |
| Mar 31, 2024 | 223.90 Mn |
| Dec 31, 2023 | 257.70 Mn |
| Sep 30, 2023 | 236.85 Mn |
| Jun 30, 2023 | 257.70 Mn |
| Mar 31, 2023 | 248.31 Mn |
| Dec 31, 2022 | 258.50 Mn |
| Sep 30, 2022 | 258.49 Mn |
| Jun 30, 2022 | 35.50 Mn |
| Mar 31, 2022 | 105.00 Mn |
| Sep 30, 2014 | 211.65 Mn |
| Jun 30, 2014 | 194.88 Mn |
| Mar 31, 2014 | 137.48 Mn |
| Dec 31, 2013 | 124.26 Mn |
| Sep 30, 2013 | 40.00 Mn |
| Jun 30, 2013 | 30.00 Mn |